Carlos Rodríguez-Nogales
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carlos Rodríguez-Nogales has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- María J. Blanco-Prieto
University of Navarra
6 shared publications - Eric Allémann
School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, Geneva, Switzerland
4 shared publications - Luca Morici
School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1211 Geneva 4, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, Rue Michel-Servet 1, 1211 Geneva 4, Switzerland
4 shared publications - Olivier Jordan
School of Pharmaceutical Sciences, University of Geneva
4 shared publications Benjamin Rossier
School of Pharmaceutical Sciences, University of Geneva, Geneva 4, Switzerland
2 shared publications- Elisa Garbayo
Department of Pharmaceutical Sciences, Faculty of Pharmacy and Nutrition, University of Navarra, C/Irunlarrea 1, 31008 Pamplona, Spain; Navarra Institute for Health Research, IdiSNA, C/Irunlarrea 3, 31008 Pamplona, Spain
2 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Elsevier in SSRN Electronic Journal
Development and validation of a UHPLC-MS/MS method for the quantification of cyclic RGD peptides in lipid nanoparticle matrices
Reliable quantification of cyclic Arg-Gly-Asp (cRGD) peptides in lipid nanoparticle formulations remains a major analytical challenge, limiting the accurate characterization of targeted nanomedicines. Here, a selective and sensitive ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed and validated for the determination of three cRGD peptides (cRGDfK, cRGDfMeV, and cRGDfC) in complex lipid matrices, providing a robust analytical approach for evaluating peptide surface functionalization. Rapid, selective, and sensitive analysis was achieved using positive electrospray ionization coupled with multiple reaction monitoring. Method validation, performed according to ICH Q2 guidelines, demonstrated excellent linearity (R² ≥ 0.99), a lower limit of quantification of 1 μg/mL for all analytes, excellent precision and accuracy, recoveries ranging from 95 to 110%, and negligible matrix effects. The validated method was successfully applied to evaluate the conjugation efficiency of cRGD peptides on the surface of solid lipid nanoparticles prepared using different functionalization strategies, revealing marked differences in peptide incorporation depending on the conjugation chemistry. Overall, the proposed UHPLC-MS/MS method provides a robust and reliable analytical tool for the characterization of cRGD-functionalized lipid nanoparticles, enabling the accurate evaluation of peptide surface functionalization.
- 2 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDevelopment and validation of a UHPLC-MS/MS method for the quantification of cyclic RGD peptides in lipid nanoparticle matrices
Reliable quantification of cyclic Arg-Gly-Asp (cRGD) peptides in lipid nanoparticle formulations remains a major analytical challenge, limiting the accurate characterization of targeted nanomedicines. Here, a selective and sensitive ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method was developed and validated for the determination of three cRGD peptides (cRGDfK, cRGDfMeV, and cRGDfC) in complex lipid matrices, providing a robust analytical approach for evaluating peptide surface functionalization. Rapid, selective, and sensitive analysis was achieved using positive electrospray ionization coupled with multiple reaction monitoring. Method validation, performed according to ICH Q2 guidelines, demonstrated excellent linearity (R² ≥ 0.99), a lower limit of quantification of 1 μg/mL for all analytes, excellent precision and accuracy, recoveries ranging from 95 to 110%, and negligible matrix effects. The validated method was successfully applied to evaluate the conjugation efficiency of cRGD peptides on the surface of solid lipid nanoparticles prepared using different functionalization strategies, revealing marked differences in peptide incorporation depending on the conjugation chemistry. Overall, the proposed UHPLC-MS/MS method provides a robust and reliable analytical tool for the characterization of cRGD-functionalized lipid nanoparticles, enabling the accurate evaluation of peptide surface functionalization.
- Open Access
- 3 June 2026
- Published by Elsevier in SSRN Electronic Journal
Development and validation of a UHPLC-MS/MS method for the quantification of cyclic RGD peptides in lipid nanoparticle matrices
Targeted solid lipid nanoparticles (SLNs) functionalized with cyclic Arg-Gly-Asp (cRGD) peptides for integrin recognition in tumor cells require robust analytical strategies for accurate peptide quantification. In this study, a selective and sensitive ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) method was developed and validated for the quantitative determination of cRGD peptides in complex lipid-based matrices. Chromatographic separation was achieved on a reversed-phase UHPLC column using gradient elution, and detection was performed by tandem mass spectrometry with electrospray ionization in positive mode (ESI⁺) operating in multiple reaction monitoring (MRM) mode. Quantifier and qualifier transitions were optimized to ensure high selectivity and sensitivity. The method was validated according to ICH Q2 guidelines through the evaluation of linearity, limits of detection and quantification, precision, accuracy, and recovery. Excellent linearity, as well as good intra- and inter-day precision and accuracy, were obtained across the investigated concentration range. The validated method was successfully applied to the quantification of cRGD peptides and to the evaluation of cRGD conjugation efficiency on the surface of SLNs. Overall, the proposed UHPLC-MS/MS method constitutes a reliable analytical tool for the characterization and quality control of cRGD-functionalized SLNs in pharmaceutical research and development.
- 3 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDevelopment and validation of a UHPLC-MS/MS method for the quantification of cyclic RGD peptides in lipid nanoparticle matrices
Targeted solid lipid nanoparticles (SLNs) functionalized with cyclic Arg-Gly-Asp (cRGD) peptides for integrin recognition in tumor cells require robust analytical strategies for accurate peptide quantification. In this study, a selective and sensitive ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) method was developed and validated for the quantitative determination of cRGD peptides in complex lipid-based matrices. Chromatographic separation was achieved on a reversed-phase UHPLC column using gradient elution, and detection was performed by tandem mass spectrometry with electrospray ionization in positive mode (ESI⁺) operating in multiple reaction monitoring (MRM) mode. Quantifier and qualifier transitions were optimized to ensure high selectivity and sensitivity. The method was validated according to ICH Q2 guidelines through the evaluation of linearity, limits of detection and quantification, precision, accuracy, and recovery. Excellent linearity, as well as good intra- and inter-day precision and accuracy, were obtained across the investigated concentration range. The validated method was successfully applied to the quantification of cRGD peptides and to the evaluation of cRGD conjugation efficiency on the surface of SLNs. Overall, the proposed UHPLC-MS/MS method constitutes a reliable analytical tool for the characterization and quality control of cRGD-functionalized SLNs in pharmaceutical research and development.
- Open Access
- 26 March 2026
- Published by Elsevier in Cancer Letters
- Vol. 647, 218454
Oral solid lipid nanoparticles of etoposide enable metronomic-like therapy with reduced toxicity in MYCN-amplified neuroblastoma
- 26 March 2026
- Published by Elsevier in Cancer Letters
- Vol. 647, 218454
Open AccessOral solid lipid nanoparticles of etoposide enable metronomic-like therapy with reduced toxicity in MYCN-amplified neuroblastoma
- Open Access
- 20 February 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 119
Protein-based nanocarrier delivering kartogenin derivative to cartilage matrix for intra-articular treatment of osteoarthritis
- 20 February 2026
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 119
Open AccessProtein-based nanocarrier delivering kartogenin derivative to cartilage matrix for intra-articular treatment of osteoarthritis
- Open Access
- 31 May 2025
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 22 (7) , 1031-1042
Recent advances in nanocrystals for arthritis drug delivery
More than 500 million people worldwide suffer from arthritis, experiencing daily pain and inflammation. Current treatments for osteoarthritis (OA) and rheumatoid arthritis (RA) are palliative, offering only symptom relief. No disease-modifying OA drugs (DMOADs) capable of restoring joint functionality and regenerating the cartilage matrix have yet been approved by the FDA or EMA. This review highlights recent advances in nanocrystals for arthritis drug delivery, including conventional nanosuspensions and novel transdermal microneedles. Special attention is given to intra-articular DMOADs formulated as nanocrystal-in-microparticles, designed to extend drug release over months. Papers and reviews with the mentioned contents and published over the last 5 years were included in the review process. New DMOADs and disease-modifying antirheumatic drugs (DMARDs) are often poorly water-soluble, limiting their clinical progress. The versatility of nanocrystals and nanosuspensions offers a potential advantage over other types of nanoparticles, as they can be adapted to various delivery systems, administration routes, and types of arthritis. Due to the avascular nature of cartilage, exploring the intra-articular route for OA management is essential. Implementing cartilage-targeted strategies or using stimuli-responsive hydrogels can further enhance their therapeutic potential.
- 31 May 2025
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 22 (7) , 1031-1042
Open AccessRecent advances in nanocrystals for arthritis drug delivery
More than 500 million people worldwide suffer from arthritis, experiencing daily pain and inflammation. Current treatments for osteoarthritis (OA) and rheumatoid arthritis (RA) are palliative, offering only symptom relief. No disease-modifying OA drugs (DMOADs) capable of restoring joint functionality and regenerating the cartilage matrix have yet been approved by the FDA or EMA. This review highlights recent advances in nanocrystals for arthritis drug delivery, including conventional nanosuspensions and novel transdermal microneedles. Special attention is given to intra-articular DMOADs formulated as nanocrystal-in-microparticles, designed to extend drug release over months. Papers and reviews with the mentioned contents and published over the last 5 years were included in the review process. New DMOADs and disease-modifying antirheumatic drugs (DMARDs) are often poorly water-soluble, limiting their clinical progress. The versatility of nanocrystals and nanosuspensions offers a potential advantage over other types of nanoparticles, as they can be adapted to various delivery systems, administration routes, and types of arthritis. Due to the avascular nature of cartilage, exploring the intra-articular route for OA management is essential. Implementing cartilage-targeted strategies or using stimuli-responsive hydrogels can further enhance their therapeutic potential.
- Top Cited PapersOpen Access
- 16 October 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 666, 124843
Cartilage-targeted drug nanocarriers for osteoarthritis therapy
- 16 October 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 666, 124843
Top Cited PapersOpen AccessCartilage-targeted drug nanocarriers for osteoarthritis therapy
- Open Access
- 7 March 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (12) , 3438-3451
Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems
Nanocrystals and nanosuspensions have become realistic approaches to overcome the formulation challenges of poorly water-soluble drugs. They also represent a less-known but versatile platform for multiple therapeutic applications. They can be integrated into a broad spectrum of drug delivery systems including tablets, hydrogels, microneedles, microparticles, or even functionalized liposomes. The recent progresses, challenges, and opportunities in this field are gathered originally together with an informative case study concerning an itraconazole nanosuspension-in-hydrogel formulation. The translational aspects, historical and current clinical perspectives are also critically reviewed here to shed light on the incoming generation of nanocrystal formulations.
- 7 March 2024
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 14 (12) , 3438-3451
Open AccessNanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems
Nanocrystals and nanosuspensions have become realistic approaches to overcome the formulation challenges of poorly water-soluble drugs. They also represent a less-known but versatile platform for multiple therapeutic applications. They can be integrated into a broad spectrum of drug delivery systems including tablets, hydrogels, microneedles, microparticles, or even functionalized liposomes. The recent progresses, challenges, and opportunities in this field are gathered originally together with an informative case study concerning an itraconazole nanosuspension-in-hydrogel formulation. The translational aspects, historical and current clinical perspectives are also critically reviewed here to shed light on the incoming generation of nanocrystal formulations.
- Open Access
- 30 December 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 651, 123754
Nanocrystal-chitosan particles for intra-articular delivery of disease-modifying osteoarthritis drugs
- 30 December 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 651, 123754
Open AccessNanocrystal-chitosan particles for intra-articular delivery of disease-modifying osteoarthritis drugs
- Open Access
- 30 November 2023
- Published by Springer Nature in Research Square
Nanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems
Nanocrystals and nanosuspensions have become realistic approaches to overcome the formulation challenges of poorly water-soluble drugs. They also represent a less-known but versatile platform for multiple therapeutic applications. They can be integrated into a broad spectrum of drug delivery systems including tablets, hydrogels, microneedles, microparticles, or even functionalized liposomes. The recent progresses, challenges, and opportunities in this field are gathered originally together with an informative case study concerning an itraconazole nanosuspension-in-hydrogel formulation. The translational aspects, historical and current clinical perspectives are also critically reviewed here to shed light on the incoming generation of nanocrystal formulations.
- 30 November 2023
- Published by Springer Nature in Research Square
Open AccessNanocrystals and nanosuspensions: an exploration from classic formulations to advanced drug delivery systems
Nanocrystals and nanosuspensions have become realistic approaches to overcome the formulation challenges of poorly water-soluble drugs. They also represent a less-known but versatile platform for multiple therapeutic applications. They can be integrated into a broad spectrum of drug delivery systems including tablets, hydrogels, microneedles, microparticles, or even functionalized liposomes. The recent progresses, challenges, and opportunities in this field are gathered originally together with an informative case study concerning an itraconazole nanosuspension-in-hydrogel formulation. The translational aspects, historical and current clinical perspectives are also critically reviewed here to shed light on the incoming generation of nanocrystal formulations.
- Open Access
- 28 September 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (24) , 3730-3738
Decoration of Squalenoyl‐Gemcitabine Nanoparticles with Squalenyl‐Hydroxybisphosphonate for the Treatment of Bone Tumors
Therapeutic perspectives of bone tumors such as osteosarcoma remain restricted due to the inefficacy of current treatments. We propose here the construction of a novel anticancer squalene‐based nanomedicine with bone affinity and retention capacity. A squalenyl‐hydroxybisphosphonate molecule was synthetized by chemical conjugation of a 1‐hydroxyl‐1,1‐bisphosphonate moiety to the squalene chain. This amphiphilic compound was inserted onto squalenoyl‐gemcitabine nanoparticles using the nanoprecipitation method. The co‐assembly led to nanoconstructs of 75 nm, with different morphology and colloidal properties. The presence of squalenyl‐hydroxybisphosphonate enhanced the nanoparticles binding affinity for hydroxyapatite, a mineral present in the bone. Moreover, the in vitro anticancer activity was preserved when tested in commercial and patient‐treated derived pediatric osteosarcoma cells. Further in vivo studies will shed light on the potential of these nanomedicines for the treatment of bone sarcomas.
- 28 September 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (24) , 3730-3738
Open AccessDecoration of Squalenoyl‐Gemcitabine Nanoparticles with Squalenyl‐Hydroxybisphosphonate for the Treatment of Bone Tumors
Therapeutic perspectives of bone tumors such as osteosarcoma remain restricted due to the inefficacy of current treatments. We propose here the construction of a novel anticancer squalene‐based nanomedicine with bone affinity and retention capacity. A squalenyl‐hydroxybisphosphonate molecule was synthetized by chemical conjugation of a 1‐hydroxyl‐1,1‐bisphosphonate moiety to the squalene chain. This amphiphilic compound was inserted onto squalenoyl‐gemcitabine nanoparticles using the nanoprecipitation method. The co‐assembly led to nanoconstructs of 75 nm, with different morphology and colloidal properties. The presence of squalenyl‐hydroxybisphosphonate enhanced the nanoparticles binding affinity for hydroxyapatite, a mineral present in the bone. Moreover, the in vitro anticancer activity was preserved when tested in commercial and patient‐treated derived pediatric osteosarcoma cells. Further in vivo studies will shed light on the potential of these nanomedicines for the treatment of bone sarcomas.